Search Results for: Tick Studies
Jim is a microbiologist and has conducted antibiotic discovery research for over 30 years in big pharma and academia. Jim is currently a supervisory microbiologist at the New Jersey Department of Health conducting viral (arboviruses and covid-19) surveillance for the state. He is starting a multi-partner plan to institute a state-wide tick surveillance and testing program for the state of New Jersey.
The Molecular Therapy Journal (Pine M., et al.) 08.01.2023, published “Development of an mRNA-lipid nanoparticle vaccine against Lyme disease.” In this study, scientists propose using a new method called “mRNA-LNP” to create a Lyme disease vaccine, similar to the successful COVID-19 vaccines. The vaccine would target a specific protein in the bacteria Borrelia burgdorferi that causes Lyme disease, called OspA. This protein is found on the surface of B. burgdorferi and is essential for its survival in ticks. By targeting this bacterium, the vaccine aims to prevent the bacteria from infecting humans when bitten by ticks.
In 1998, there was an alum-adjuvanted recombinant OspA protein vaccine release called LYMErix™, that showed to decrease Lyme disease by 75% within a year, but the vaccine was removed from the market in 2002, just four years after its release. Since then, there has been no FDA-approved vaccine for Lyme disease, while cases continue to rise.
International Journal of General Medicine (Johnson, L; et al.) published 6.17.23 “Does Biological Sex Matter in Lyme Disease? The Need for Sex-Disaggregated Data in Persistent Illness.” In this study researchers examined the outcome differences between men and women with Lyme disease. Investigators analyzed self-reported clinical data from 2170 patients in the MyLymeData patient registry, as well as review of other Lyme disease studies.
US Biologic, Inc., developer and distributor of oral-delivery vaccines, has announced USDA Conditional Licensure of its novel oral vaccine against the spread of Borrelia burgdorferi in wildlife.
Dr. Daniel Cameron graduated from the University of Minnesota School of Medicine and their Department of Epidemiology. He completed residencies at both Beth Israel Medical Center and Mt. Sinai in New York City. Dr. Cameron has led International Lyme and Associated Disease Society (ILADS) twice as their president. He is widely recognized as author of ILADS practice guidelines, Lyme disease science blogs, and Inside Lyme Podcasts. His latest book is titled, “An Expert’s Guide on Navigating Lyme disease.” He continues to see patients in his private practice in Mt. Kisco, New York.